Athanassios Argiris

Summary

Affiliation: University of Texas Health Science Center
Country: USA

Publications

  1. doi request reprint Current status and future directions in induction chemotherapy for head and neck cancer
    Athanassios Argiris
    Division of Hematology Oncology, Department of Medicine, UT Health Science Center at San Antonio, Cancer Therapy and Research Center, 7979 Wurzbach Road MC8232, Zeller Building 4th Floor, Room Z418, San Antonio, TX 78229, United States Electronic address
    Crit Rev Oncol Hematol 88:57-74. 2013
  2. doi request reprint Pemetrexed in head and neck cancer: a systematic review
    Athanassios Argiris
    Division of Hematology Oncology, University of Texas Health Science Center at San Antonio and Cancer Therapy and Research Center, San Antonio, TX 78229, United States
    Oral Oncol 49:492-501. 2013
  3. pmc Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial
    Athanassios Argiris
    Division of Hematology Oncology, University of Texas Health Science Center at San Antonio, Cancer Therapy and Research Center, 7979 Wurzbach Rd, MC8232, Zeller Building, 4th Floor, Room Z418, San Antonio, TX 78229, USA
    J Clin Oncol 31:1405-14. 2013
  4. pmc Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck
    A Argiris
    Department of Medicine, Division of Hematology Oncology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA
    Ann Oncol 24:220-5. 2013
  5. pmc Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies
    Athanassios Argiris
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Invest New Drugs 30:1575-84. 2012
  6. pmc Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancer
    Athanassios Argiris
    Head and Neck Cancer Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, United States
    Oral Oncol 47:961-6. 2011
  7. doi request reprint Stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: results of a phase I dose-escalation trial
    Dwight E Heron
    Department of Radiation Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, USA
    Int J Radiat Oncol Biol Phys 75:1493-500. 2009
  8. pmc Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients
    Christine H Chung
    Division of Hematology Oncology, Department of Medicine, Vanderbilt Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232 6307, USA
    Cancer Epidemiol Biomarkers Prev 19:358-65. 2010
  9. pmc Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology Group
    Athanassios Argiris
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    Cancer 115:4504-13. 2009
  10. pmc Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer
    Athanassios Argiris
    University of Pittsburgh Medical Center Cancer Pavilion, 5th Floor, Pittsburgh, PA 15232, USA
    J Clin Oncol 28:5294-300. 2010

Detail Information

Publications49

  1. doi request reprint Current status and future directions in induction chemotherapy for head and neck cancer
    Athanassios Argiris
    Division of Hematology Oncology, Department of Medicine, UT Health Science Center at San Antonio, Cancer Therapy and Research Center, 7979 Wurzbach Road MC8232, Zeller Building 4th Floor, Room Z418, San Antonio, TX 78229, United States Electronic address
    Crit Rev Oncol Hematol 88:57-74. 2013
    ..In addition, patient selection based on individual disease characteristics may identify ideal candidates for induction therapy. These developments may result in personalized therapeutic regimens that improve clinical outcomes. ..
  2. doi request reprint Pemetrexed in head and neck cancer: a systematic review
    Athanassios Argiris
    Division of Hematology Oncology, University of Texas Health Science Center at San Antonio and Cancer Therapy and Research Center, San Antonio, TX 78229, United States
    Oral Oncol 49:492-501. 2013
    ..In particular, the role of pemetrexed as a radiosensitizer and potential alternative to cisplatin warrants investigation. More research is needed to clearly define the role of pemetrexed in HNC treatment...
  3. pmc Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial
    Athanassios Argiris
    Division of Hematology Oncology, University of Texas Health Science Center at San Antonio, Cancer Therapy and Research Center, 7979 Wurzbach Rd, MC8232, Zeller Building, 4th Floor, Room Z418, San Antonio, TX 78229, USA
    J Clin Oncol 31:1405-14. 2013
    ..We hypothesized that the addition of gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, to docetaxel would enhance therapeutic efficacy in squamous cell carcinoma of the head and neck (SCCHN)...
  4. pmc Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck
    A Argiris
    Department of Medicine, Division of Hematology Oncology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA
    Ann Oncol 24:220-5. 2013
    ....
  5. pmc Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies
    Athanassios Argiris
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Invest New Drugs 30:1575-84. 2012
    ..We evaluated the combination of dasatinib, an inhibitor of SFK and other kinases, and cetuximab, an anti-EGFR monoclonal antibody...
  6. pmc Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancer
    Athanassios Argiris
    Head and Neck Cancer Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, United States
    Oral Oncol 47:961-6. 2011
    ..Validation is warranted in future studies specifically designed to detect biomarker associations...
  7. doi request reprint Stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: results of a phase I dose-escalation trial
    Dwight E Heron
    Department of Radiation Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, USA
    Int J Radiat Oncol Biol Phys 75:1493-500. 2009
    ..To evaluate the safety and efficacy of stereotactic body radiotherapy (SBRT) in previously irradiated patients with squamous cell carcinoma of the head and neck (SCCHN)...
  8. pmc Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients
    Christine H Chung
    Division of Hematology Oncology, Department of Medicine, Vanderbilt Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232 6307, USA
    Cancer Epidemiol Biomarkers Prev 19:358-65. 2010
    ....
  9. pmc Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology Group
    Athanassios Argiris
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    Cancer 115:4504-13. 2009
    ..Docetaxel and irinotecan have single-agent antitumor activity in squamous cell carcinoma of the head and neck (SCCHN). The authors sought to evaluate their combination in the treatment of patients with recurrent or metastatic SCCHN...
  10. pmc Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer
    Athanassios Argiris
    University of Pittsburgh Medical Center Cancer Pavilion, 5th Floor, Pittsburgh, PA 15232, USA
    J Clin Oncol 28:5294-300. 2010
    ..We incorporated cetuximab, a chimeric monoclonal antibody against the epidermal growth factor receptor (EGFR), into the induction therapy and subsequent chemoradiotherapy of head and neck cancer (HNC)...
  11. doi request reprint Prognostic factors in patients with high-risk locally advanced salivary gland cancers treated with surgery and postoperative radiotherapy
    Trevor M Feinstein
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    Head Neck 33:318-23. 2011
    ..This study was designed to identify the factors associated with the outcome after standard treatment with surgery and postoperative radiotherapy (RT) for locally advanced salivary gland cancers...
  12. pmc A phase I study of concurrent chemotherapy (paclitaxel and carboplatin) and thoracic radiotherapy with swallowed manganese superoxide dismutase plasmid liposome protection in patients with locally advanced stage III non-small-cell lung cancer
    Ahmad A Tarhini
    University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, USA
    Hum Gene Ther 22:336-42. 2011
    ..There were no dose-limiting toxicities reported in all three dosing tiers. It is concluded that the oral administration of MnSOD PL is feasible and safe. The phase II recommended dose is 30 mg...
  13. pmc A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303)
    Athanassios Argiris
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA
    Cancer 117:3374-82. 2011
    ..Bortezomib, an inhibitor of the 26S proteasome and NF-κB, may have antitumor activity in adenoid cystic carcinoma (ACC). Preclinical studies have shown synergy between bortezomib and doxorubicin...
  14. pmc Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer
    Athanassios Argiris
    Biostatistics Facility, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, USA
    J Clin Oncol 29:1140-5. 2011
    ..We hypothesized that bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), will potentiate the activity of pemetrexed, a multitargeted antifolate, in squamous cell carcinoma of the head and neck (SCCHN)...
  15. ncbi request reprint Staging and monitoring of small cell lung cancer using [18F]fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET)
    Victoria Kut
    Department of Medicine, Division of Hematology Oncology, Northwestern University, Chicago, IL, USA
    Am J Clin Oncol 30:45-50. 2007
    ..18F]Fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) scan is widely used for the staging evaluation of nonsmall cell lung cancer, however, its use in small cell lung cancer (SCLC) remains investigational...
  16. ncbi request reprint Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck
    Athanassios Argiris
    Division of Hematology Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois 60611, USA
    Cancer 101:2222-9. 2004
    ....
  17. ncbi request reprint Revisiting induction chemotherapy for head and neck cancer. References and reviews
    Athanassios Argiris
    Division of Hematology Oncology, Department of Medicine, Feinberg School of Medicine and Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA
    Oncology (Williston Park) 19:932-4, 939; discussion 939-45. 2005
    ..Platinum/taxane combinations are the preferred regimens for further study in the induction setting and a suitable platform with which to investigate the addition of novel targeted agents...
  18. ncbi request reprint Long-term results of a phase III randomized trial of postoperative radiotherapy with or without carboplatin in patients with high-risk head and neck cancer
    Athanassios Argiris
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15232, USA
    Laryngoscope 118:444-9. 2008
    ..The role of postoperative radiotherapy and carboplatin in squamous cell carcinoma of the head and neck (SCCHN) has not been established...
  19. ncbi request reprint Combined analysis of molecular and clinical predictors of gefitinib activity in advanced non-small cell lung cancer: epidermal growth factor receptor mutations do not tell the whole story
    Athanassios Argiris
    Division of Hematology Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA
    J Thorac Oncol 1:52-60. 2006
    ..The study of molecular markers may identify the subset of patients who are the most appropriate to treat with these agents...
  20. ncbi request reprint Pemetrexed: a novel antifolate agent enters clinical practice
    Victoria Kut
    Department of Medicine, Division of Hematology Oncology, The Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60611, USA
    Expert Rev Anticancer Ther 4:511-22. 2004
    ..Future studies will better define and likely expand the role of pemetrexed for the treatment of cancer...
  21. ncbi request reprint Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy
    Athanassios Argiris
    Feinberg School of Medicine, Division of Hematology Oncology, Northwestern University, Chicago, IL 60611, USA
    J Clin Oncol 22:262-8. 2004
    ..To evaluate the outcome of elderly patients with head and neck cancer undergoing palliative chemotherapy...
  22. ncbi request reprint Induction chemotherapy for resectable non-small-cell lung cancer
    Jyoti D Patel
    Department of Medicine, Feinberg School of Medicine, Northwestern University, Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA
    Oncology (Williston Park) 18:1591-602; discussion 1602-3, 1606, 1611-2. 2004
    ..Randomized trials are under way to better define the role of induction therapy in the multimodality treatment of NSCLC...
  23. doi request reprint Phase II study of everolimus (RAD001) in previously treated small cell lung cancer
    Ahmad Tarhini
    University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA
    Clin Cancer Res 16:5900-7. 2010
    ..Mammalian target of rapamycin (mTOR) is a promising target in small cell lung cancer (SCLC). We designed a phase II study of everolimus, an mTOR inhibitor, in previously treated, relapsed SCLC...
  24. ncbi request reprint Revisiting induction chemotherapy for head and neck cancer
    Athanassios Argiris
    Division of Hematology Oncology, Northwestern University Chicago, Illinois 60611, USA
    Oncology (Williston Park) 19:759-70. 2005
    ..Platinum/taxane combinations are the preferred regimens for further study in the induction setting and a suitable platform with which to investigate the addition of novel targeted agents...
  25. pmc Intratumoral epidermal growth factor receptor antisense DNA therapy in head and neck cancer: first human application and potential antitumor mechanisms
    Stephen Y Lai
    Departments of Otolaryngology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
    J Clin Oncol 27:1235-42. 2009
    ..A phase I clinical trial was conducted to evaluate the safety and biologic effects of EGFR AS...
  26. ncbi request reprint A phase II trial of doxorubicin and interferon alpha 2b in advanced, non-medullary thyroid cancer
    Athanassios Argiris
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh, UPMC Cancer Pavilion, 5th Floor, Pittsburgh, PA 15232, USA
    Invest New Drugs 26:183-8. 2008
    ..The combination of doxorubicin and interferon alpha is supported by preclinical data. We sought to evaluate the efficacy of this combination in patients with advanced thyroid cancer...
  27. pmc Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer
    Athanassios Argiris
    Hematology Oncology and Head and Neck Cancer Program, and Radiation Oncology, University of Pittsburgh, Pittsburgh, PA, USA
    Clin Cancer Res 17:5755-64. 2011
    ....
  28. ncbi request reprint Induction chemotherapy for head and neck cancer: will history repeat itself?
    Athanassios Argiris
    Division of Hematology Oncology, University of Pittsburgh, Pittsburgh, Pennsylvania 15232, USA
    J Natl Compr Canc Netw 3:393-403. 2005
    ..A number of randomized trials are planned or currently ongoing to investigate concurrent chemoradiotherapy with or without induction. These trials are anticipated to redefine the role of induction chemotherapy for head and neck cancer...
  29. ncbi request reprint Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas
    Michalis V Karamouzis
    Division of Hematology Oncology, University of Pittsburgh, Pittsburgh, Pennsylvania 15232, USA
    JAMA 298:70-82. 2007
    ..Given the biological importance of epidermal growth factor receptor (EGFR) in cancer development and progression, EGFR inhibitors have emerged as promising novel therapies...
  30. ncbi request reprint Phase I trial of carboplatin and etoposide in combination with panobinostat in patients with lung cancer
    Ahmad A Tarhini
    University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, 5150 Centre Avenue 555, Pittsburgh, PA 15232, U S A
    Anticancer Res 33:4475-81. 2013
    ..A phase I trial consisting of panobinostat (a HDAC inhibitor), carboplatin and etoposide was conducted in patients with lung cancer...
  31. pmc Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma
    Sarah Wheeler
    Department of Otolaryngology, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA
    Clin Cancer Res 18:2278-89. 2012
    ..Tumor (n = 50) EGFR and EGFRvIII mRNA levels were quantified using real-time PCR...
  32. doi request reprint Head and neck cancer
    Athanassios Argiris
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15232, USA
    Lancet 371:1695-709. 2008
    ..We review the epidemiology, molecular pathogenesis, diagnosis and staging, and the latest multimodal management of squamous cell carcinoma of the head and neck...
  33. ncbi request reprint Deferring planned neck dissection following chemoradiation for stage IV head and neck cancer: the utility of PET-CT
    Jayakar V Nayak
    Department of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Laryngoscope 117:2129-34. 2007
    ..To determine whether combined positron emission tomography and computed tomography (PET-CT) may be of value in deferring planned neck dissections for patients with advanced head and neck squamous cell carcinoma (HNSCC)...
  34. ncbi request reprint Update on the role of EGFR inhibitors in cancer therapeutics
    Michalis V Karamouzis
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    Cancer Treat Res 135:257-75. 2007
  35. ncbi request reprint Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer
    Athanassios Argiris
    Division of Hematology Oncology, The Feinberg School of Medicine, Northwestern University, 676 N St Clair, Suite 850, Chicago, IL 60611, USA
    Lung Cancer 43:317-22. 2004
    ..To evaluate the efficacy of single-agent gefitinib (Iressa, ZD1839), an oral, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, as first-line compassionate use therapy for advanced non-small-cell Lung cancer (NSCLC)...
  36. doi request reprint Management of patients treated with chemoradiotherapy for head and neck cancer without prophylactic feeding tubes: the University of Pittsburgh experience
    Brian T McLaughlin
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania 15232, USA
    Laryngoscope 120:71-5. 2010
    ..Mucositis and dysphagia are common complications of chemoradiotherapy (CRT) for head and neck cancer that may necessitate nutritional support with a gastrostomy tube (G-tube)...
  37. ncbi request reprint Phase I and pharmacokinetic study of docetaxel, irinotecan, and celecoxib in patients with advanced non-small cell lung cancer
    Athanassios Argiris
    Division of Hematology Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, The Robert H Lurie Comprehensive Cancer Center, Chicago, IL, USA
    Invest New Drugs 24:203-12. 2006
    ..We studied the toxicities, potential pharmacokinetic interactions, and preliminary antitumor activity of the combination of docetaxel and irinotecan with celecoxib, a selective cyclooxygenase-2 inhibitor...
  38. pmc Targeting GPCR-mediated p70S6K activity may improve head and neck cancer response to cetuximab
    Neil E Bhola
    Departments of Pharmacology and Chemical Biology, Otolaryngology, Medicine, and Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Clin Cancer Res 17:4996-5004. 2011
    ..We hypothesized that targeting GPCR-induced EGFR-independent signaling would improve the efficacy of EGFR inhibition...
  39. ncbi request reprint A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer
    Athanassios Argiris
    Division of Hematology Oncology, University of Pittsburgh, Pittsburgh, Pennsylvania 15232, USA
    Cancer Biol Ther 5:766-70. 2006
    ..Perifosine is an oral alkylphospholipid that inhibits AKT phosphorylation and has shown preclinical antitumor activity in head and neck cancer cell lines and xenografts...
  40. pmc The impact of health insurance status on the survival of patients with head and neck cancer
    Joseph Kwok
    University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA
    Cancer 116:476-85. 2010
    ..The main outcome measures were overall survival and relapse-free survival...
  41. ncbi request reprint Phase I dendritic cell p53 peptide vaccine for head and neck cancer
    Patrick J Schuler
    Authors Affiliations Cancer Immunology Program Biostatistics Facility, University of Pittsburgh Cancer Institute Departments of Pathology and Otolaryngology, University of Pittsburgh School of Medicine Division of Hematology Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania Department of Medicine, Hematology Oncology, University of Texas San Antonio Cancer Center, San Antonio, Texas and Department of Otolaryngology, University of Ulm, Germany
    Clin Cancer Res 20:2433-44. 2014
    ..p53 accumulation in head and neck squamous cell carcinoma (HNSCC) cells creates a targetable tumor antigen. Adjuvant dendritic cell (DC)-based vaccination against p53 was tested in a phase I clinical trial...
  42. ncbi request reprint Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go
    Jyoti D Patel
    Department of Medicine, Northwestern University Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA
    Crit Rev Oncol Hematol 50:175-86. 2004
    ..The goal of ongoing and future investigation is to identify which patients may benefit from this new therapeutic approach...
  43. doi request reprint Race and health disparities in patient refusal of surgery for early-stage non-small cell lung cancer: a SEER cohort study
    Rohtesh S Mehta
    Division of General Internal Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Ann Surg Oncol 19:722-7. 2012
    ..The aim of the present study is to determine the influence of race and health disparities on refusal of recommended potentially curative surgery...
  44. ncbi request reprint Erlotinib, Erlotinib-Sulindac versus Placebo: A Randomized, Double-Blind, Placebo-Controlled Window Trial in Operable Head and Neck Cancer
    Neil D Gross
    Authors Affiliations Division of Head and Neck Surgery, Department of Otolaryngology, Oregon Health and Science University, Portland, Oregon Division of Hematology Oncology, Department of Internal Medicine Department of Pharmacology and Chemical Biology Biostatistics Facility, University of Pittsburgh, University of Pittsburgh Cancer Institute Departments of Otolaryngology and Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania Department of Otolaryngology, University of Kansas Medical Center, Kansas City, Kansas Women s Health Integrated Research Center, Gynecologic Cancer Center of Excellence, Annandale, Virginia Division of Hematology Oncology, Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts and Department of Pharmacology, University of Minnesota, Minneapolis, Minnesota
    Clin Cancer Res 20:3289-98. 2014
    ..We conducted a randomized, double-blind, placebo-controlled window trial of erlotinib, an EGFR inhibitor; erlotinib plus sulindac, a nonselective COX inhibitor; versus placebo...
  45. ncbi request reprint Intensive concurrent chemoradiotherapy for head and neck cancer with 5-Fluorouracil- and hydroxyurea-based regimens: reversing a pattern of failure
    Athanassios Argiris
    Division of Hematology Oncology, Northwestern University, The Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center, Chicago, Illinois 60611, USA
    Oncologist 8:350-60. 2003
    ..The incorporation of induction chemotherapy may improve the results of treatment by targeting systemic micrometastatic disease...
  46. pmc Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples
    Athanasios Kotsakis
    Departments of Pathology, Medical Oncology, Immunology and Otolaryngology, University of Pittsburgh Cancer Institute and University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    J Immunol Methods 381:14-22. 2012
    ..Arginase I expression or stimulated ROS production assessed by flow cytometry are useful markers for MDSC subsets only in fresh samples...
  47. ncbi request reprint Clinical applications of gene therapy in head and neck cancer
    Michalis V Karamouzis
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Curr Gene Ther 7:446-57. 2007
    ..Systemic delivery of gene therapy may be also possible, albeit with several limitations. In this review we will discuss the rationale, delivery methods, and accumulated clinical data with cancer gene therapy in SCCHN...
  48. ncbi request reprint PET scan assessment of chemotherapy response in metastatic paraganglioma
    Athanassios Argiris
    Division of Hematology Oncology, The Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois 60611, USA
    Am J Clin Oncol 26:563-6. 2003
    ..It is suggested that metabolic imaging with PET scans is superior to anatomical imaging with CT scans for the monitoring of patients with paragangliomas...
  49. ncbi request reprint Malignant thymoma associated with fatal myocarditis and polymyositis in a 32-year-old woman with a history of hairy cell leukemia
    Adi Gidron
    Division of Hematology Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA
    Am J Clin Oncol 29:213-4. 2006